剖宫产术后失血预防中的氨甲环酸:随机对照试验的最新系统综述与Meta分析
该系统综述与Meta分析纳入50项随机对照试验,评估静脉氨甲环酸在低危和高危剖宫产产妇中预防失血的疗效与安全性。氨甲环酸可降低失血量>1000 mL的风险、平均总失血量及输血需求,在切口前给药(而非断脐后)与更大获益相关。证据质量低至极低(低危人群)和中度(高危人群),缺乏高质量证据妨碍得出强结论,需进一步研究。
要点
- 氨甲环酸可降低低危和高危剖宫产产妇失血量>1000 mL的风险、平均总失血量及输血需求。
- 氨甲环酸增加非血栓栓塞性不良事件风险,但基于有限数据未增加血栓栓塞事件发生率。
- 切口前给药与更大获益相关,而断脐后给药未显示此关联。
核心结论
- 氨甲环酸可能降低剖宫产失血风险,高危患者获益更高,但缺乏高质量证据妨碍得出强结论。
- 切口前给予氨甲环酸(而非断脐后)与更大获益相关。
- 需进一步研究,尤其在高危人群和评估氨甲环酸给药时机方面,以确认或反驳这些发现。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(通过PubMed)、Embase、Cochrane Library、ClinicalTrials.gov和WHO ICTRP门户,从建库至2022年4月(2022年10月和2023年2月更新),无语言限制,并探索灰色文献。
- 纳入50项随机对照试验(其中6项仅高危患者,2项以前列腺素为对照),评估静脉氨甲环酸联合标准宫缩剂与安慰剂、标准治疗或前列腺素比较。
- 使用修订版Cochrane偏倚风险工具(RoB 2.0)评估质量,RevMan 5.4采用随机效应模型进行统计分析。
主要发现
- 氨甲环酸降低低危和高危患者失血量>1000 mL的风险、平均总失血量及输血需求。
- 氨甲环酸在次要结局中有益,包括血红蛋白水平下降和额外宫缩剂需求减少。
- 氨甲环酸增加非血栓栓塞性不良事件风险,但基于有限数据未增加血栓栓塞事件发生率。
- 切口前给药(而非断脐后)与更大获益相关。
- 证据质量:低危人群结局为低至极低,高危亚组多数结局为中度。
临床怎么用
- 原文结论未给出具体临床推荐,仅指出氨甲环酸可能降低剖宫产失血风险,高危患者获益更高,但缺乏高质量证据妨碍强结论。
局限性
- 缺乏高质量证据妨碍得出强结论。
- 非血栓栓塞性不良事件和血栓栓塞事件的数据有限。
- 需进一步研究,尤其在高危人群和评估氨甲环酸给药时机方面,以确认或反驳这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tranexamic acid is a cost-effective intervention for the prevention of postpartum hemorrhage among women who undergo cesarean delivery, but the evidence to support its use is conflicting. We conducted this meta-analysis to evaluate the efficacy and safety of tranexamic acid in low- and high-risk cesarean deliveries. DATA SOURCES: We searched MEDLINE (via PubMed), Embase, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform portal from inception to April 2022 (updated October 2022 and February 2023) with no language restrictions. In addition, grey literature sources were also explored. STUDY ELIGIBILITY CRITERIA: All randomized controlled trials that investigated the prophylactic use of intravenous tranexamic acid in addition to standard uterotonic agents among women who underwent cesarean deliveries in comparison with a placebo, standard treatment, or prostaglandins were included in this meta-analysis. METHODS: We used the revised Cochrane Risk of Bias tool (RoB 2.0) to assess the quality of the included randomized controlled trials. RevMan 5.4 was used to conduct all statistical analyses using a random-effects model. RESULTS: We included 50 randomized controlled trials (6 in only high-risk patients and 2 with prostaglandins as the comparator) that evaluated tranexamic acid in our meta-analysis. Tranexamic acid reduced the risk for blood loss >1000 mL, the mean total blood loss, and the need for blood transfusion in both low- and high-risk patients. Tranexamic acid was associated with a beneficial effect in the secondary outcomes, including a decline in hemoglobin levels and the need for additional uterotonic agents. Tranexamic acid increased the risk for nonthromboembolic adverse events but, based on limited data, did not increase the incidence of thromboembolic events. The administration of tranexamic acid before skin incision, but not after cord clamping, was associated with a large benefit. The quality of evidence was rated as low to very low for outcomes in the low-risk population and moderate for most outcomes in the high-risk subgroup. CONCLUSION: Tranexamic acid may reduce the risk for blood loss in cesarean deliveries with a higher benefit observed in high-risk patients, but the lack of high-quality evidence precludes any strong conclusions. The administration of tranexamic acid before skin incision, but not after cord clamping, was associated with a large benefit. Additional studies, especially in the high-risk population and focused on evaluating the timing of tranexamic acid administration, are needed to confirm or refute these findings.
引用
- Cheema HA, Ahmad AB, Ehsan M, et al. Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2023. PMID: 37311484. doi:10.1016/j.ajogmf.2023.101049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。